Kronfli AP, Lehman E, Yamane K, et al. - Researchers undertook this retrospective cohort analysis to investigate if there exist disparities in outcomes and cost depending on whether patients were administered dexmedetomidine or propofol when receiving transcatheter aortic valve replacement (TAVR) with monitored anesthesia care (MAC). Participants were 161 patients who received TAVR with MAC between May 2014 and March 2019. There was a propofol-only (n = 58) group and a dexmedetomidine-only (n = 103) group. Findings revealed that in-hospital outcomes, 30-day outcomes, or total cost of the patient's hospitalization did not differ significantly based on the use of dexmedetomidine vs propofol in patients receiving TAVR.